Specialty Pharmacy

Top news of the day from across the health care landscape.

Vaccine found to provide durable protection against the “death star” HIV strain, which is notably hard to fight.

Researchers aimed to determine the potential pathology of encephalitis as a complication of immunotherapy treatment.

Top news of the day from across the health care landscape.

Erdafitinib (Balversa, Janssen) is the first FGFR inhibitor to receive FDA approval for the treatment of patients with metastatic bladder cancer marked by FGFR gene mutations.

Top news of the day from across the health care landscape.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

Results from an ongoing safety trial of tofacitinib demonstrated an increased risk of blood clots and death associated with a 10-mg twice daily dose of tofacitinib in patients with rheumatoid arthritis.

Top news of the day from across the health care landscape.

Investigators find that radiation equivalent to 3 CT scans prompts the growth of the p53 mutation in mice.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

If approved, tazemetostat, a first-in-class EZH2 inhibitor, would be indicated for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

More colorectal cancer cases are being diagnosed in adults under the age of 50, with younger adults presenting with more advanced disease than those older than 50 years.

Long-term use of ivacaftor and other drugs that correct detects in the cystic fibrosis gene could potentially prevent chronic infections from developing.

Top news of the day from across the health care landscape.

Stigma around behaviors such as smoking or drinking found to effect funding for associated cancers.

There are currently no approved therapies for methylmalonic acidemia, a rare and life-threatening disease caused by mutations in the MUT gene.

Top news of the day from across the health care landscape.

Rituximab-pvvr (Ruxience, Pfizer) is approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Researchers achieve first success in linking a solid tumor with blood biomarkers, which is often an indicator of whether a patient with breast cancer will remain in remission.

If approved, pembrolizumab in combination with lenvatinib will be indicated for the first-line treatment of advanced unresectable hepatocellular carcinoma.

Individuals with persistent HIV in the cells of their cerebrospinal fluid are more likely to experience neurocognitive impairment.

Top news of the day from across the health care landscape.

Scientific advances could lead to earlier prevention and treatment of infection, helping to avoid irreversible or severe chronic diseases.

A novel potential biomarker test could identify patients who would benefit from more advanced lung cancer screening.

Top news of the day from across the health care landscape.

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.